Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurocrine BiosciencesFRA:NB3 -0.34%93 Cash Ratio is 0.45 as of Jun. 2026, which is 83% below its 10-year median of 2.62. GuruFocus rates FRA:NB3 with a GF Score™ of 93/100 and a GF Value™ of €170.50 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 935 Drug Manufacturers companies, Neurocrine Biosciences ranks worse than 57.97% on this metric.
Neurocrine Biosciences has a Cash Ratio of 0.45. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for Neurocrine Biosciences's Cash Ratio or its related term are showing as below:
FRA:NB3'
s Cash Ratio Range Over the Past 10 Years
Min: 0.45 Med: 2.62 Max: 18.94
Current: 0.45
During the past 13 years, Neurocrine Biosciences's highest Cash Ratio was 18.94. The lowest was 0.45. And the median was 2.62.
FRA:NB3's Cash Ratio is ranked worse than 57.97% of 935
companies
in the Drug Manufacturers industry
Industry Median: 0.62
vs FRA:NB3: 0.45
Neurocrine Biosciences (FRA:NB3) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:NB3 vs VTRS, UTHR, ELAN: Cash Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences Cash Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences (FRA:NB3) has a Cash Ratio of 0.45 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Neurocrine Biosciences and its competitors. This is 83% below median its historical median of 2.62. Over the past decade, Neurocrine Biosciences' Cash Ratio has ranged from 0.45 to 18.94. According to the industry distribution chart, Neurocrine Biosciences ranks #542 out of 935 companies in the Drug Manufacturers industry, placing it in the top 58%.
Is Neurocrine Biosciences' Cash Ratio too high?
Neurocrine Biosciences' current Cash Ratio of 0.45 is 83% below median its 10-year median of 2.62. Over the past 10 years, this metric has ranged from a low of 0.45 to a high of 18.94. The Drug Manufacturers industry median Cash Ratio is 0.62. Neurocrine Biosciences' value of 0.45 is 27.4% below this industry median. Based on the distribution chart, Neurocrine Biosciences ranks #542 out of 935 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Neurocrine Biosciences has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Cash Ratio compare to VTRS and UTHR?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #542 out of 935 companies for Cash Ratio. This places Neurocrine Biosciences in the lower half of its industry. The industry median Cash Ratio is 0.62. Neurocrine Biosciences' value of 0.45 is 27.4% below this benchmark. Historically, Neurocrine Biosciences' own Cash Ratio has ranged from 0.45 to 18.94 over the past decade. While the company's 10-year median is 2.62 vs. the industry median of 0.62, Neurocrine Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Drug Manufacturers company?
The median Cash Ratio among Drug Manufacturers companies is 0.62, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurocrine Biosciences's current Cash Ratio of 0.45 is 27.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median Cash Ratio is 0.62 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current Cash Ratio is 0.45, which is 83% below median its own 10-year median of 2.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Modestly Undervalued. The stock's GF Value™ is €170.50, compared to a current price of €131.85 — trading 22.7% below its estimated fair value. The current Cash Ratio is 0.45, which is 83% below median its 10-year median of 2.62 and 27.4% below the Drug Manufacturers industry median of 0.62. Neurocrine Biosciences' overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current Cash Ratio is 0.45 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of €131.85 is trading 22.7% below its estimated GF Value™ of €170.50.
GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.
Key valuation signals for FRA:NB3:
Cash Ratio: 0.45 (83% below median its 10-year median of 2.62)
GF Value™: €170.50 vs. price of €131.85 (22.7% below fair value)
Industry Position: 27.4% below the Drug Manufacturers median (#542 of 935)
No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
93GF Score
Get the complete analysis for FRA:NB3
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NB3 has been successfully added to your 
